Criteria for the validation of surrogate endpoints in randomized experiments.
Explore this paper's citation graph
Summary
It is argued that two other quantities must be considered in the validation of a surrogate endpoint: RE, the effect of Z on T relative to that ofZ on S, and gamma Z, the association between S and T after adjustment for Z.
- Type
- article
- Published
- 1998-09-01
- Cited by
- 452
- References
- 26
- OpenAlex
- https://openalex.org/W2011453559
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:34483627
Keywords
Surrogate endpoint, Statistics, Confidence interval, Clinical endpoint, Surrogate data
References
- Validation of intermediate end points in cancer research.
- SAS System for Mixed Models
- On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection.
- CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine
- Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.
- Categorical Data Analysis
- Surrogate endpoints in clinical trials: cardiovascular diseases.
- Modelling progression of CD4-lymphocyte count and its relationship to survival time.
- Does chemotherapy improve survival in advanced breast cancer? A statistical overview.
- Perspective: validating surrogate markers--are we being naive?
- A Class of Bivariate Distributions
- Fieller's theorem vs. The delta method for significance intervals for ratios
- Families of Bivariate Distributions
- Surrogate end points in clinical trials.
- Global cross-ratio models for bivariate, discrete, ordered responses.
- Correlated binary regression using a quadratic exponential model
- Surrogate End Points in Clinical Trials: Are We Being Misled?
- Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.
- Marginal Modeling of Correlated Ordinal Data Using a Multivariate Plackett Distribution
- Statistical validation of intermediate endpoints for chronic diseases.
Cited by
- A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma
- The Mediation Proportion: A Structural Equation Approach for Estimating the Proportion of Exposure Effect on Outcome Explained by an Intermediate Variable
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
- Markers for nutrition studies: review of criteria for the evaluation of markers
- GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.
- Prognostic and surrogate markers for outcome in the treatment of pulmonary tuberculosis
- Estimating Percentile-Specific Causal Effects: A Case Study of Micronutrient Supplementation, Birth Weight, and Infant Mortality
- Intermediate markers: Surrogacy assessment using principal stratification and multi-state models
- Quantitative science methods for biomarker validation in chemoprevention trials
- Composite endpoint analysis for assessing surrogacy with censored data
- Επινεφριδιακά ανδρογόνα σε μετεμμηνοπαυσιακές γυναίκες με και χωρίς καρκίνο του μαστού και διερεύνηση της σχέσης τους με την TH1/TH2 ανοσιακή απάντηση
- Evidence needs for licensing and reimbursement
- Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?
- Biomarkers and surrogate endpoints in kidney disease
- Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life?
- Operational risk with Excel and VBA : applied statistical methods for risk management
- Advances in Clinical Trial Biostatistics
- Impact of Informative Censoring on Statistics Used in the Validation of Surrogate Endpoints in Oncology
- Progression-free survival as a surrogate for overall survival: a new paradigm?
- Prostate Cancer: Prognostic factors, markers of outcome and design of clinical trials
Related papers
- On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection.
- NON-INFERIORITY TRIALS WITH A PRIMARY SURROGATE ENDPOINT: AN INCREASING PHENOTYPE IN CARDIOVASCULAR TRIALS
- Evaluation of a surrogate marker: validity and efficiency
- Abstract 19637: Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990- 2011
- Surrogate endpoints in randomized cardiovascular clinical trials
- Surrogate endpoints in clinical trials: cancer.
- Non-inferiority Trials Using a Surrogate Marker as a Primary Endpoint: An Increasing Phenotype in Cardiovascular Trials
- Progression-free survival as a surrogate for overall survival: a new paradigm?